Overview

Coronary Vasomotor Response After Riociguat Exposure

Status:
Withdrawn
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
The aim of the study is to assess the effects of intracoronary Riociguat on coronary blood flow in subjects with coronary artery disease and to compare this effect with the intracoronary nitroglycerin, a coronary vasodilator widly used to treat patients with coronary artery disease.
Phase:
Phase 2
Details
Lead Sponsor:
Bayer
Treatments:
Nitroglycerin
Riociguat